Mark Marmur, V.P., Global Corporate Communications & Investor Relations
Contact:
Exclusive European License & Supply Agreement with Recordati
On June 24, 2025, Amarin and Recordati entered into an exclusive long-term license and supply agreement to commercialize VAZKEPA® (icosapent ethyl) in Europe.
Compelling Strategic & Financial Benefits
New strategic pathway to further maximize VAZKEPA in Europe
Leverages Recordati’s long and extensive heritage in cardiovascular disease, cardiovascular portfolio and vast geographical presence across Europe
Amarin remains global manufacturer and supplier of VAZKEPA
- $25M upfront cash and milestone payments totaling up to $150M contingent upon Recordati achieving predefined annual commercial net sales levels
- Supply-based revenues, including royalties for supply of product
Immediately strengthens financial position in near- and long-term
Allows Amarin to right-size global organization for go-forward operations
- Global restructuring expected to generate ~$70M cost savings over next 12 months; vast majority from Europe operations
Amarin’s European Success
Pricing & Reimbursement secured and access opened to over half of eligible patient population in Western Europe
Commercially available in 10 European and Central and Eastern Europe markets
Unlocked regional access accounting for 91% of eligible patient population in Italy shortly after national reimbursement; country now ready for full commercial launch
Strong medical advocacy and support across Europe; inclusion of VAZKEPA in multiple European and national guidelines & protocols
Revised potential strategies for resubmission in France and Germany identified
Amarin’s Growth Strategy: Realizing Future Growth Potential through Key Strengths
2
3
4
VASCEPA/VAZKEPA has enormous untapped global value
Strengthened financial foundation
Capturing value from multiple revenue streams
Exploring strategic actions to maximize shareholder value
1
Advancing Amarin’s Strategy
Strong Position for the Future
2
3
4
1
VASCEPA/VAZKEPA has enormous untapped global value
Strengthened financial foundation
Capturing value from multiple revenue streams
Exploring strategic actions to maximize shareholder value
Mark Marmur, V.P., Global Corporate Communications & Investor Relations
Contact:
Exclusive European License & Supply Agreement with Recordati
On June 24, 2025, Amarin and Recordati entered into an exclusive long-term license and supply agreement to commercialize VAZKEPA® (icosapent ethyl) in Europe.
Compelling Strategic & Financial Benefits
New strategic pathway to further maximize VAZKEPA in Europe
Leverages Recordati’s long and extensive heritage in cardiovascular disease, cardiovascular portfolio and vast geographical presence across Europe
Amarin remains global manufacturer and supplier of VAZKEPA
- $25M upfront cash and milestone payments totaling up to $150M contingent upon Recordati achieving predefined annual commercial net sales levels
- Supply-based revenues, including royalties for supply of product
Immediately strengthens financial position in near- and long-term
Allows Amarin to right-size global organization for go-forward operations
- Global restructuring expected to generate ~$70M cost savings over next 12 months; vast majority from Europe operations
Amarin’s European Success
Pricing & Reimbursement secured and access opened to over half of eligible patient population in Western Europe
Commercially available in 10 European and Central and Eastern Europe markets
Unlocked regional access accounting for 91% of eligible patient population in Italy shortly after national reimbursement; country now ready for full commercial launch
Strong medical advocacy and support across Europe; inclusion of VAZKEPA in multiple European and national guidelines & protocols
Revised potential strategies for resubmission in France and Germany identified
Advancing Amarin’s Strategy
Mark Marmur, V.P., Global Corporate Communications & Investor Relations
Contact:
Strong Position for the Future
2
3
4
1
VASCEPA/VAZKEPA has enormous untapped global value
Strengthened financial foundation
Capturing value from multiple revenue streams
Exploring strategic actions to maximize shareholder value
Exclusive European License & Supply Agreement with Recordati
On June 24, 2025, Amarin and Recordati entered into an exclusive long-term license and supply agreement to commercialize VAZKEPA® (icosapent ethyl) in Europe.
Compelling Strategic & Financial Benefits
New strategic pathway to further maximize VAZKEPA in Europe
Leverages Recordati’s long and extensive heritage in cardiovascular disease, cardiovascular portfolio and vast geographical presence across Europe
Amarin remains global manufacturer and supplier of VAZKEPA
- $25M upfront cash and milestone payments totaling up to $150M contingent upon Recordati achieving predefined annual commercial net sales levels
- Supply-based revenues, including royalties for supply of product
Immediately strengthens financial position in near- and long-term
Allows Amarin to right-size global organization for go-forward operations
- Global restructuring expected to generate ~$70M cost savings over next 12 months; vast majority from Europe operations
Amarin’s European Success
Pricing & Reimbursement secured and access opened to over half of eligible patient population in Western Europe
Commercially available in 10 European and Central and Eastern Europe markets
Unlocked regional access accounting for 91% of eligible patient population in Italy shortly after national reimbursement; country now ready for full commercial launch
Strong medical advocacy and support across Europe; inclusion of VAZKEPA in multiple European and national guidelines & protocols
Revised potential strategies for resubmission in France and Germany identified
Advancing Amarin’s Strategy